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Summary There is considerable interest in immunohistochemical markers of proliferation which are suitable
for use on routinely fixed clinical material. The novel proliferation-associated antibody Ki-SI shows promise in
this respect. In this study we have: (i) defined the pattern of Ki-Si labelling relative to the cell cycle phase; (ii)
investigated the labelling pattern with Ki-Si on a human breast cell line (ZR75) under varying proliferative
conditions induced by serum deprivation and refeeding; (iii) examined in a flow cytometric study Ki-Sl
staining in archival, clinical breast carcinoma samples. In exponentially growing cells Ki-S1 showed a marked
cell cycle phase-specific variation in staining intensity which increased linearly through the S-phase, was high
in G2 and reached its peak in mitosis. Ki-Si staining intensity mirrored the changes in proliferative activity of
ZR75 cells during serum deprivation and refeeding. In a small series of human breast carcinomas, Ki-S1
staining intensity correlated with S-phase fraction (SPF) derived from DNA profiles. The antigen labelled by
Ki-SI is extremely robust, resisting degradation by fixation and by an aggressive enzymic tissue disaggregation
method. Ki-Sl warrants further investigation as a proliferation-related marker, particularly for routine clinical
application.
Many proteins are involved in the process of cell prolifera-
tion and some of them have a regulatory role. Identification
and characterisation of proliferation-related proteins may
give insight into important aspects of cell and tumour
biology. In addition, the ability to use such proteins as
markers of proliferative activity may be of practical use in
clinical situations.
Traditionally, proliferation has been assessed by methods
involving the incorporation of tritiated thymidine (3H-TdR)
or by techniques based on mitotic counting. The use of
3H-TdR has the disadvantages, for clinical situations, of
involving a radioactive isotope and requiring the relatively
laborious technique of autoradiography to detect labelled
cells. Nevertheless, 3H-TdR labelling has yielded clinically
useful data (see for example Silvestrini et al., 1989). Mitotic
counting suffers from being extremely laborious if performed
correctly, requiring large numbers ofcells to be counted since
mitosis is a relatively rare event (Quinn & Wright, 1990).
DNA flow cytometry is quick and statistically precise and
can yield very useful data (see for example O'Reilly et al.,
1990). However, it does require an expensive piece of equip-
ment and may not be applicable for very small lesions or
situations in which retention of tissue morphology is of
particular importance. Thus, the immunohistological method
of assessing proliferation by detecting the presence of
proliferation-related proteins is appealing. Tissue architecture
is maintained, the methodology is relatively simple and the
use of radioactivity is avoided. However, to be useful as a
clinical marker of proliferation, a protein must be robust, its
presence must given unambiguous information about pro-
liferative state and the results obtained should give useful
insight into the clinical course of the disease.
Probably the most popular immunohistological marker of
proliferative activity so far has been the monoclonal antibody
Ki-67 (Gerdes et al., 1983). This antibody has also been used
to detect proliferative cells by flow cytometry (Baisch et al.,
1987). A major drawback of this antibody is that the epitope
which it labels is extremely labile and does not withstand
conventional fixation procedures. It can thus only be used on
frozen tissue. Antibodies directed against other cell cycle
related proteins have been used as proliferation markers in
recent years. There has been particular interest in antibodies
against proliferating cell nuclear antigen (PCNA), a protein
which functions as an auxiliary factor to DNA polymerase 6
(Lee et al., 1989). One such antibody called PCI0 (Waseem et
al., 1990) has recently become commercially available and it
has the advantage of labelling cells in routinely fixed clinical
material. It has been shown to give useful information about
proliferative activity in a range of normal tissues and in some
tumours (Hall et al., 1990; Yu et al., 1991). However, in a
number of types of carcinoma, for example breast, results
with PC10 have not correlated either with other proliferative
markers or with clinical outcome (Leonardi et al., 1992;
Gillett et al., 1992).
In the present study, we have used the power of multi-
parametric flow cytometry to define the nature of labelling
seen with a new proliferation-related antibody, Ki-Sl. In
addition, the changes in labelling with Ki-SI were studied in
a situation in which the rate of proliferation underwent large
variation. Finally, the feasibility of detecting Ki-Sl labelling
in nuclei prepared from paraffin sections of human breast
carcinomas was investigated.
Materials and methods
Tissue culture
The ZR75 cell line was derived from a human breast car-
cinoma. These cells were grown as monolayers in Dulbecco's
modified Eagles medium (Gibco) with 10% foetal calf serum,
10-8 M oestradiol and antibiotics. Cells were maintained in
exponential growth at 37°C in a humidified atmosphere con-
taining 5% CO2.
Bromodeoxyuridine incorporation
Bromodeoxyuridine (BrdUrd) was dissolved in Earle's
balanced salt solution at a concentration of 100ylM and
added to flasks so as to yield a final concentration of 10ylM.
BrdUrd solution, pre-warmed to 37°C, was added to flasks
30min before cells were harvested.
Preparation andfixation ofsuspensions
The monolayers were disaggregated with a 0.25% solution of
buffered Trypsin (Difco). A cell count was made and the cells
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were washed with ice cold phosphate buffered saline (PBS).
The suspension was divided into aliquots of 3 x 106 cells.
Ki-SI was shown in pilot experiments to give a similar
staining pattern with both nuclei and intact cells. Detergent-
extracted nuclei were used for Ki-S1 staining because they
gave better quality profiles both in terms of DNA and
antibody staining. Extracted nuclei were produced by treat-
ment of cells on ice with a buffered solution of 0.25%
Nonidet P-40 (Sigma), nuclei were then washed with PBS
and fixed for 5 min at - 20°C in pure methanol, which was
subsequently diluted to 70% with distilled water.
Antibodies
The mouse anti-BrdUrd antibody was purchased from Bec-
ton Dickinson. PCIO was kindly supplied by Professor David
Lane, Dundee. Ki-SI was generated by immunising BALB/c
mice with crude nuclear extracts from the human histiocytic
lymphoma cell line U937 (for more details see Kreipe et al.,
1992). Batches of Ki-SI antibody were not consistent in
terms of protein content and staining intensity. Thus an
experiment was performed with each batch of antibody to
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determine the optimum concentration. All results in this
paper were produced from a single batch of KiSI.
Stainingprotocols
BrdUrd Intact cell preparations were acid denatured with
0.1 M HCl for 10min at 37°C, washed with PBS and then
stained with 20 lAl of mouse anti-BrdUrd antibody for 60 min
at room temperature. After washing in PBS, cells were
stained with 10gIl of fluorescein conjugated F(ab)2 rabbit
anti-mouse antibody (Dako) for 30 min at room temperature
in the dark.
PCIO and Ki-SJ The staining protocol was the same as that
described for BrdUrd with the exception that the acid
denaturation step was omitted. Optimum amounts of
antibody were first determined and found to be 5 1l1 of PC1O
and 0.1IlA of Ki-SI per million cells. For both primary
antibodies a second stage comprising 4gIl of the F(ab)2 FITC
conjugate (Dako) was used. For all antibodies a negative
control (F(ab)2 FITC alone) was prepared for each sample.
DNA staining At the end of the antibody staining proce-
dure, preparations were washed with PBS and resuspended in
Brd Urd Isoton II (Coulter) containing 50 gml m' propidium iodide 7 and 200 gig ml-' RNAase (Sigma). Cells were left in the dark
at room temperature for a minimum of 30 min and,
immediately prior to running on the flow cytometer, the ,.SoPC10 suspensions were passed through a 25 g needle to reduce
SPF clumping.
Serum deprivation experiment
Cells were dispensed into Falcon flasks and allowed to plate.
Three days later the cultures were rinsed with sterile PBS and
medium added with a serum content of 1%. After 7 days in
low serum, the cells were returned to normal growth medium
containing 10% serum. Cell growth was monitored and the
monolayers subcultured as they approached confluence. Sam-
ples of cells were harvested after 4 and 7 days in low serum
and 3, 4 and 7 days after the cells were returned to 10%
serum. Flow cytometry was performed as described. The rom the DNA results from this experiment are illustrated in Figures 1 and 2
J by refeeding. and are for a single experiment, which was repeated and
showed the same pattern of changes.
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Figure 2 Plots of Ki-SI staining of ZR75 cells. Day 0 represents normal exponentially growing cells, day 4 and day 7 illustrate the
effects of serum reduction on the staining pattern. Day 10 (3 days after cells returned to 10% serum) day 11 (4 days after refeeding)
and day 14 (7 days after refeeding) illustrate recovery of Ki-SI staining.
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Metaphase-arrest experiment
Cells were plated in Falcon flasks and in petri-dishes. After 5
days growth under standard conditions, the cells were
incubated with 0.1 g ml-l vincristine sulphate (Oncovin,
Lilly). Flasks and petri dishes were harvested at 0, 2, 4, 6 and
8 h after adding the drug. Cells from the flasks were fixed
both intact and after detergent extraction for flow cytometry.
Monolayers in petri-dishes were fixed for 30 min with 3:1
solution of methanol:acetic acid, air dried and stained with
haematoxylin and eosin (H&E). From each of two replicate
dishes per time point 1,000 cells were counted and the
number of mitotic figures recorded.
Staining ofclinical carcinoma samples
Nuclear suspensions were prepared from two 50jtm paraffin
sections of each of 15 cases of carcinoma of the breast as
described previously (Camplejohn et al., 1989). These cases
had previously had DNA flow cytometry performed on them
and were selected to give a wide range of SPF values and, in
the case of aneuploid tumours, to have at least 20% of cells
with an aneuploid DNA content. Each suspension was split
into two aliquots; one aliquot was stained with Ki-Sl as
described for ZR75 cells and the other aliquot was used to
prepare a negative control. Samples were counter-stained for
DNA and run on the flow cytometer as described for ZR75
cells.
Flow cytometry
Samples were analysed on a Becton Dickinson FACSCAN
with a 15 mV argon laser emitting at an excitation
wavelength of 488 nm. Data were collected in list mode
recording forward scatter, side scatter, green fluorescence
(from fluorescein) and red fluorescence (from PI). Ten thou-
sand events were collected for each sample. Linear amplifier
settings were used throughout except in the case of BrdUrd,
for which fluorescence was so strong that a log amplifier was
used. Acquisition and data analysis were achieved using the
Lysys II software supplied by Becton Dickinson.
Data analysis
In all cases before data analysis debris and cell doublets were
excluded by gating on pulse area:width for the PI signal.
S-phasefraction (SPF) SPF was calculated by the method
of Baisch et al. (1975) and for aneuploid clinical tumours by
a modification of this method (Camplejohn et al., 1989).
PCJO and BrdUrd The clear distinction between labelled
S-phase cells and effectively unlabelled GI and G2 cells
enabled a simple estimation of the percentage of positive
cells.
Ki-SI A clear distinction between positive and negative cells
was not possible with Ki-SI staining. This was due to the
presence of weakly stained G, cells and a gradual increase in
labelling intensity around the cell cycle. Thus discrete groups
of 'labelled' and 'unlabelled' cells could not be identified.
This problem was compounded by changes in fluorescence
intensity during the serum deprivation experiment. Thus the
mean fluorescence intensity, either of all cells or of cells
within particular cell cycle phases, was calculated as a
measure of the strength of labelling with Ki-Sl.
Results
Serum deprivation experiment
S-phase measurements The results of the three methods of
estimating S-phase, namely SPF, BrdUrd labelling and PCIO
staining on detergent-extracted nuclei, are illustrated in
Figure 1. All three methods give similar results in terms of
measuring changes in the number of S-phase cells throughout
the experiment. The percentage of S-phase cells in exponen-
tially growing ZR75 cells is typically around 20% as in this
experiment. On being placed in medium containing 1%
serum the proliferative activity of the cells reduces until by 7
days only about 1% of cells are in S-phase. On refeeding
with 10% serum, the cells recover their proliferative activity,
such that by 7 days after refeeding, normal levels are
achieved.
Ki-SI staining In exponentially growing cells a small tail of
quite strongly Ki-SI labelled GI cells is apparent (first panel
- Figure 2) but these cells (which are discussed later) con-
stitute only about 5% of all G, cells. The rest of the GI cells
exhibit relatively uniform weak staining with the level of
staining then increasing linearly through S-phase and
reaching a maximum in cells with a G2/M DNA content.
There is a 4-fold increase in staining intensity through the
cell cycle with this antibody (Table I) in exponentially grow-
ing cells.
Following serum deprivation the intensity of Ki-Sl stain-
ing showed a marked fall (Figure 2 and Table I) with a
virtual disappearance of strongly labelled cells by 7 days of
serum deprivation. Only residual weak labelling is seen with
Ki-SI at this time. Following refeeding with medium contain-
ing 10% serum, there was a recovery in the intensity of
staining. Thus 7 days after refeeding with 10% serum, stain-
ing intensity with Ki-Sl had returned close to normal levels.
Staining in GI cells is weak even in exponentially growing
cells and thus these cells have little scope to show a reduction
in Ki-Sl staining intensity during serum deprivation. In con-
trast, not only do the numbers of S and G2/M cells reduce
during serum deprivation, but also the intensity of staining in
these cells cycle phases shows marked reduction (Table I).
Metaphase-arrest experiment
This experiment was performed for two reasons. First and
foremost was to explain the small tail of relatively strongly
labelled G, cells shown in region 2 (R2) of the first plot in
Figure 3. This plot illustrates Ki-Sl labelling in control
exponentially-growing ZR75 cells. About 5% of all GI cells
show strong Ki-Sl labelling and are found in R2 of this plot.
We had suspected that these were cells which had recently
left mitosis. This supposition is supported by the finding that
2 h after addition of vincristine (VCR), the number of GI
cells in R2 was reduced by a factor of five and by 4 h after
VCR (second plot in Figure 3) R2 is effectively empty and
remains empty until the end of the experiment (final plot of
Figure 3).
Over the same time course there is an increase of cells with
a G2/M DNA content and most of these cells fall in R3 of
the plots in Figure 3. The increase in cells in R3 (i.e. the most
strongly Ki-Sl positive cells) is in good agreement with the
Table I Ki-SI staining intensity in ZR75 breast cancer cells during
serum deprivation and refeeding
Meanfluorescence intensity
Time point Treatment All cells G, cells S cells G2/M cells
Day 0 Exponentially 203 130 331 565
growing cells
Day 4 Four days of
serum
deprivation
Day 7 Seven days of
serum
deprivation
Day 10 Three days
after serum
refeeding
Day 14 Seven days
after serum
refeeding
94 63 162 308
73 64 137 171
80 50 147 272
170 96 229 465660 R.S. CAMPLEJOHN et al.
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Figure 3 Ki-SI fluroescence is plotted against DNA content for control cells (upper left) 4 h after VCR addition (upper right) and
8 h after VCR (bottom). Region 2 (R2) defines a small population of strongly labelled GI cells in control cultures. Region 3 (R3)
defines a population of cells with 4C DNA content which express maximum Ki-Sl fluorescence.
increase in the number of mitotic figures counted micro-
scopically (Figure 4). It is clear from all three parameters
plotted in Figure 4 that metaphase-degeneration is occurring
as the accumulation of mitoses is not linear with 3% of cells
accumulating in the first 2 h but only just over 1% in each
2 h period thereafter. Therefore, we have not attempted to fit
straight lines to the data.
Interestingly, the data in Figure 3 were obtained from
detergent-treated, alcohol fixed cells and it might have been
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Figure 4 Three measures of VCR-induced accumulation of cells
with 4C DNA content are plotted. Solid points represent the
increase over controls of cells with a 4C DNA content, calculated
from the DNA profiles. Crosses depict the increase in high
fluorescence cells in R3 of Figure 3. The open circles described
the increase in mitotic figures counted microscopically.
expected that detergent treatment would lead to loss of
mitotic cells. However, parallel samples from non-detergent
treated cells were run and gave the same results. Further, the
result from the flow cytometry of detergent-treated cells was
in good agreement with microscopic counts.
Ki-SJ staining ofclinical breast cancer samples
It is clear from the data presented here and from other
studies we have performed, that Ki-SI gives strong staining
even on nuclei extracted from sections of paraffin-embedded
clinical material.
Table II gives a summary of the DNA profiles and the
intensity of Ki-Si staining seen in 15 breast cancer speci-
Table II SPF vs Ki-SI staining for 15 cases of carcinoma of the
breast
Mean Ki-SJ
staining
Case Ploidy SPF % intensity
I D 1.6 89
2 A 19.1 423
3 D 1.7 81
4 D 1.6 81
5 A 2.0 220
6 D 1.0 90
7 D 2.7 54
8 A 2.1 113
9 A 16.5 626
10 A 13.5 291
11 A 8.3 251
12 A 11.8 500
13 A 13.1 750
14 A 9.4 599
15 A 31.0 189
NB: Foraneuploidtumours, both SPFandtheKi-SI resultsaregiven
for the aneuploid cells only.FLOW CYTOMETRIC ASSESSMENT OF KI-SI IN BREAST CANCER 661
800
C)
UM
° 600
G)
._
400
0)
a) 4) *: 400.
CB
n
._6
0
.
.
/
/ 0
0
0 10 20 30
S-phase fraction (%)
Figure 5 The SPF (%) is plotted against the mean fluorescence
intensity of staining with Ki-S1 for fifteen cases of carcinoma of
the breast. The crosses represent results for diploid tumours. The
solid points represent results for DNA aneuploid tumours and
for both SPF and Ki-S1 fluorescence results were calculated for
the aneuploid cells alone. The solid line was calculated by linear
regression analysis excluding one outlying value (see text) while
the broken line was fitted to all the data.
mens. The quality of the DNA profiles in this series was
good, the samples yielding a mean CV of 3.9 (range 3.2-6.2).
The calculation of a percentage of positive Ki-Sl cells by
comparing the Ki-SI sample with the matching negative
control was not very informative. This is because, as for
ZR75 cells many tumour cells exhibited weak staining with a
wide variation of intensity within the cell cycle. In highly
proliferative tumours and, indeed, in most aneuploid
tumours irrespective of SPF, over 90% of cells showed some
Ki-SI staining (results not shown). However, the intensity of
Ki-Si staining does correlate with SPF (Figure 5) with a
linear regression analysis yielding a correlation coefficient of
0.5 (P = 0.03). This is despite one outlying sample (case
15-Table I) which had the highest SPF value but a low
intensity of Ki-SI staining. This particular tumour exhibited
a very high level of necrosis on tissue sections. Excluding this
case the correlation is considerably stronger (r = 0.8;
P<0.001).
A consistent finding was that in aneuploid tumours, stain-
ing was stronger in the aneuploid component than in the
diploid component.
Discussion
The results of this study concerning the use of PC1O after
detergent extraction to detect S-phase cells are in good agree-
ment with earlier reports (Landberg & Roos, 1991; Wilson et
al., 1992). The results from the present study also show a
good correlation between SPF from DNA histograms,
BrdUrd labelling and PC1O staining after detergent extrac-
tion. There are small systematic differences between the three
estimates but the pattern of change through serum depriva-
tion and refeeding is very consistent.
The situation with Ki-SI staining is more complex. When
antibodies such as these are used in immunohistochemistry
there are often problems in quantifying the labelling. On
sections, two aspects of the strength of labelling could be
assessed, namely the percentage of positive cells but also the
intensity of labelling. Often compromises are made so as to
yield a numerical assessment of one or both of these aspects
of labelling. Flow cytometry has the advantage of measuring
fluorescence intensity quantitatively. However, even with this
technique there may be difficulties in describing changing
staining patterns with simple numbers. Ki-SI shows con-
siderable variation in staining intensity around the cell cycle
with unperturbed, exponentially growing cells. At least 90%
of cells in rapidly growing cultures express detectable levels
of the Ki-SI antigen. However, when cell proliferation is
slowed by serum deprivation, the intensity of labelling with
Ki-SI decreases and it becomes impossible to define 'positive'
from 'negative' cells adequately (see Figure 2). Thus, in this
study we have used mean fluorescence intensity as the
measure of strength of staining. Unfortunately, it is difficult
to compare this parameter with results obtained on tissue
sections unless static cytometry is available, as the human eye
is very poor at judging staining intensity.
Despite difficulties in quantification, it is clear that the
level of Ki-Si staining shows a marked reduction during
serum deprivation, reflecting the reduction in proliferative
activity. By 7 days in low serum strongly labelled cells have
virtually disappeared and only a weak residual staining is
seen. On refeeding with 10% serum containing medium,
staining with Ki-SI returned close to normal levels (Figure 2
and Table I). Thus throughout this experiment staining inten-
sity with this antibody reflected the changes in proliferative
activity as defined by BrdUrd labelling, SPF and PCIO label-
ling.
As Ki-Si is a novel antibody, there are no previous flow
cytometric studies available. Data in Figure 2 and Table I
show that this antibody exhibits a marked cell cycle phase
specific staining pattern with G2/M cells being approximately
four times more strongly labelled on average than GI cells.
However, it can be seen in Figure 2, that the staining pattern
is quite complex with a small percentage of GI cells
exhibiting quite strong labelling and labelling in G2/M being
heterogeneous. This staining pattern shows marked sim-
ilarities with that previously described for another prol-
iferation-related antibody Ki-67 (Landberg et al., 1990).
These authors in an elegant three parameter comparison of
Ki-67, anti-PCNA and DNA staining showed that the
heavily Ki-67 labelled GI cells had recently left mitosis and
that the most heavily labelled cells with 4C DNA content
were mitotic cells. With the aid of a metaphases-arrest experi-
ment, we showed that a similar situation exists with Ki-Sl.
Thus, GI cells recently produced by mitosis retain con-
siderable Ki-Sl staining for 2-4 h after leaving mitosis.
Staining intensity in most GI cells is fairly weak. Staining
intensity increases linearly through S-phase, is high in G2 and
reaches its peak in mitosis. Despite the similar pattern of
labelling displayed by Ki-SI and Ki-67, the limited evidence
available so far does not suggest that the antigens which they
label are identical. Despite recent progress (Gerdes et al.,
1991), the antigen labelled by Ki-67 has not been directly
identified due to its extreme lability but it would seem to be a
large molecule consisting of two parts of 345 and 395 kD.
Preliminary evidence suggests that the Ki-SI antigen, also as
yet unidentified, has a much smaller molecular weight
(Kreipe et al., 1992). However, at this preliminary stage, it
can clearly not be ruled out that the antigens for Ki-67 and
Ki-SI are related if not identical.
The experience with immunohistochemical detection of
proliferation-related proteins in breast cancer is mixed. The
anti-PCNA monoclonal antibody PC1O has the advantage of
working on paraffin-embedded material. Unfortunately,
staining with PC1O in breast carcinoma does not seem to
correlate with other clinicopathological variables such as
tumour grade, steroid receptor content and other pro-
liferative markers (Leonardi et al., 1992). Nor from our own
studies does PCIO labelling predict clinical outcome (Gillett
et al., 1992). In contrast, a number of studies have found a
correlation between Ki-67 staining and a variety of
clinicopathological variables (Crispino et al., 1989; Isola et
al., 1990; Leonardi et al., 1992). In addition, some small
studies suggest a prognostic role for Ki-67 staining in breast
cancer (Bouzubar et al., 1989; Gasparini et al., 1989; Wintzer
et al., 1991). Unfortunately most of these studies are on small
cohorts of patients and with short follow-up. A principal
disadvantage with Ki-67, however, is that it requires frozen662 R.S. CAMPLEJOHN et al.
material. In the present pilot study, Ki-Sl labelling was
found to correlate with SPF. Further Ki-SI labelling detected
immunohistochemically on tissue sections has been found to
be a strong predictor of clinical outcome in breast cancer
(Sampson et al., 1992a,b). An important characteristic of the
antigen labelled by Ki-SI is its extreme resistance to degrada-
tion. In the present study, strong Ki-SI labelling was seen in
nuclei which had undergone routine histological fixation and
processing, followed by an aggressive disaggregation proce-
dure involving low pH and concentrated pepsin digestion.
In summary, early results with Ki-Si from this and other
studies support its role as a proliferative marker, which is of
prognostic value in breast cancer. Although results with Ki-
SI are clearly preliminary, the epitope which it labels is
extremely robust. Further, in this study, the labelling seen
with ZR75 cells was clearly proliferation-related. In a small
series of breast carcinomas, Ki-S1 labelling correlated with
S-phase fraction determined from DNA profiles.
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